Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Company Ltd (OP: ESALF )

64.97 +0.97 (+1.52%)
Streaming Delayed Price Updated: 12:47 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eisai Company Ltd

< Previous 1 2 Next >
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of  
Via Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... 
Via Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
 
Via Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer... 
Via Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
 
Via Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
 
Via Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
 
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
 
Via Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
 
Via Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
 
Via Benzinga
The 7 Best Growth Stocks to Buy for February 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
 
Via Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. 
Via Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
 
Via Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
 
Via Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that... 
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
 
Via Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
 
Via Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
 
Via Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
 
Via Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
Via Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
The  
Via Benzinga
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically... 
Via Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s... 
Via Benzinga
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.